B-type natriuretic peptide: A strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department

Coronary Artery Disease

Volumn 20, Issue 2, 2009, Pages 143-149

  Bassan, Roberto ^a   Tura, Bernardo R ^b   Maisel, Alan S ^c  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Department of Clinical Research   (France)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Acute coronary syndrome; Acute myocardial infarction; Angina pectoris; Chest pain; Natriuretic peptide; Prognosis

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL EVALUATION; DEATH; DIAGNOSTIC PROCEDURE; EMERGENCY WARD; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PEPTIDE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; ST SEGMENT ELEVATION; SURVIVOR; THORAX PAIN; ACUTE DISEASE; ANGINA PECTORIS; BLOOD; EMERGENCY HEALTH SERVICE; MIDDLE AGED; PREDICTION AND FORECASTING; RISK ASSESSMENT; ROC CURVE; STATISTICAL MODEL; TIME; UPREGULATION;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; BIOLOGICAL MARKERS; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; TIME FACTORS; UP-REGULATION;

EID: 66349111768     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283292ac6     Document Type: Article

References (41)

1. De Winter RJ, Koster RW, Sturk A, Sanders GT. Value of myoglobin, troponin T, and CKMB mass in ruling out acute myocardial infarction in the emergency room. Circulation 1995; 92:3401-3407.
2. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284:835-842.
3. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al.; for the PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an International Trial of 9461 patients. Circulation 2000; 101:2557-2567.
4. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al.; for the GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291:2727-2733.
5. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167.
6. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al.; for the Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFt). Circulation 2003; 107:1278-1283.
7. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50:2357-2368.
8. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40:437-445.
9. Bassan R, Potsch A, Maisel A, Tura B, Villacorta H, Nogueira MV, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur Heart J 2005; 26:234-240.
10. Staub D, Nusbaumer C, Zellweger MJ, Jonas N, Wild D, Pfisterer ME, et al. Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J 2006; 151:1223-1230.
11. De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345:1014-1021.
12. Omland T, Persson A, Ng L, O'Brian R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106:2913-2918.
13. Morrow DA, de Lemos JA, Sabatine MS, Murphy AS, Demopoulos LA, DiBattiste PM, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST elevation myocardial infarction. B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003; 41:1264-1272.
14. Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 2003; 42:1909-1916.
15. Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP, et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndrome. Circulation 2004; 110:128-134.
16. Heenschen C, Hamm CW, Mitrovic V, Lantelme N-H, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndrome. Circulation 2004; 110:3206-3212.
17. Lindahl B, Lindback J, Jernberg T, Johnston N, Stridsberg M, Venge P, et al. Serial analysis of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes. A fragmin and fast revascularization during instability in coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 2005; 45:533-541.
18. Jarai R, Iordanova N, Jarai R, Reffetseder A, Woloszczuk W, Gyongyosi M, et al. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur Heart J 2006; 26:250-256.
19. Khan SQ, Quinn P, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 2008; 94:40-43.
20. Jaffe A. Caveat Emptor. Am J Med 2003; 115:241-244.
21. Apple FS, Jesse RL, Newby LK, Wu AHB, Christenson RH. National Academy of Clinical Biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007; 115:e352-e355.
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 1988; 44:837-845.
23. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. 1st ed. West Sussex, England: John Wiley and Sons; 2004. p. 25.
24. Björklund E, Jernberg T, Johanson P, Venge P, Dellborg M, Wallentin L, et al.; the ASSENT-2 and ASSENT-PLUS Study Groups. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction. Heart 2006; 92:735-740.
25. Erhardt L, Herlitz J, Bossaert L, Halinen M, Keltai M, Koster R, et al. Task force on the management of chest pain. Eur Heart J 2002; 23:1153-1176.
26. Boie ET. Initial evaluation of chest pain. Emerg Med Clin N Am 2005; 23:937-957.
27. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/ AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:652-726.
28. Estrada JLN, Rubinstein F, Bahit MC, Rolandi F, deArenaza DP, Gabay JM, et al. NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndrome. Am Heart J 2006; 151:1100.e1-1100.e7.
29. Riezebos RK, Ronner E, Tijssen JGP, Laarman GJ. NT-proBNP serum levels reflect severity and extent of ischemia in patients admitted with non-ST-elevation acute coronary syndrome. Acute Cardiac Care 2006; 8:51-57.
30. Sadanandan S, Cannon CP, Chekuri K, Murphy SA, DiBattiste PM, Morrw DA, et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:564-568.
31. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, et al. Acute changes in circulating natriuretic peptide level in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44:1988-1995.
32. Jernberg T, James S, Lindahl B, Johnston N, Stridsberg M, Venge P, et al. Natriuretic peptides in unstable coronary artery disease. Eur Heart J 2004; 25:1486-1493.
33. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischemia induced by dynamic exercise in patients with angina pectoris. Clin Sci 1995; 88:551-556.
34. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J,Wergeland R, et al.; for the PEACE Investigators. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007; 50:205-214.
35. Kwan G, Isakson SR, Beede J, Clopton P, Maisel AS, Fitzgerald RL. Short-term serial sampling of natriuretic peptides in patients presenting with chest pain. J Am Coll Cardiol 2007; 49:1186-1192.
36. Kaul S, Senior R, Firschke C, Wang X, Lindner JR, Villanueva FS, et al. Incremental value of cardiac imaging in patients presenting to the emergency department with chest pain and without ST-segment elevation: a multicenter study. Am Heart J 2004; 148:129-136.
37. Rinkevich D, Kaul S, Wang KL, Belcik T, Kalvaitis S, Lepper W, et al. Regional left ventricular perfusion and function in patients presenting to the emergency department with chest pain and no ST-segment elevation. Eur Heart J 2005; 26:1606-1611.
38. James SK, Lindbäck J, Tilly J, Siegbahn A, Venge P, Armstrong P, et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndrome: GUSTO-IV Substudy. J Am Coll Cardiol 2006; 48:1146-1154.
39. Windhausen F, Hirsch A, Sanders GT, Cornel JH, Fischer J, van Straalen JP, et al.; for the ICTUS Investigators. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndrome (ICTUS) Substudy. Am Heart J 2007; 153:485-492.
40. Mueller C. The use of B-type natriuretic peptides in coronary artery disease: utile or futile? J Am Coll Cardiol 2007; 50:215-216.
41. De Lemos JA, Morrow DA. Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation acute coronary syndrome. Am Heart J 2007; 153:450-453.